CTLA4 and neoplasm: In this study, we identified that systemic administration of [131I]-KN046 as a promising strategy noninvasively monitored PD-L1/CTLA-4 expression in vivo during an antitumor response with SPECT/CT, capable of increasing immunotherapy response rates and the survival rate of B16F10 tumor-bearing mice significantly.